# Haplox Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/haplox-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.haplox.cn
- Total disclosed funding: $32M
- Latest round: Series D (Jul 26, 2022)
- Investors on record: 8

## About

Based in Shenzhen, China, and established in 2014, Haplox Biotechnology Co., LTD is a biotechnology company that engages in genetic testing services. The company has a research and development team of more than 80 people. The company’s founder and CEO, Dr. Mingyan Xu, is a Ph.D. in Biomedicine from the University of New Mexico. The company has established R&D centers in both Shenzhen and the USA. The company has applied for more than 10 national and international patents and 18 software copyrights. In July 2020, it launched the covid-19 anti-epidemic system HCOVIS. In March 2019, the company was accredited by the College of American Pathologists' Laboratory Accreditation Program.

The company mainly provides genetic testing services, including tumor testing, genetic disease screening, and the detection of infectious diseases based on COVID-19. It uses liquid biopsy, gene sequencing, artificial intelligence and other technologies and data analysis methods to provide accurate genomics diagnosis solutions and full-process management solutions. Its CUBE-ctDNA sequencing technology can identify trace quantities of circulating tumor DNA in the blood, with sensitivity as low as 0.05%. Its business services more than three hundred hospitals in more than thirty provinces in China.

## Funding rounds

- Series D, Jul 26, 2022 — SB China Venture Capital, CNCB (Hong Kong) Investment, Beijing Tongrentang Senior Care Investment Management
- Series B, Apr 3, 2020 — Yuanzhi Venture Capital
- Series B, Jun 28, 2018 — Shenzhen Capital Real Estate Fund
- Series A, Dec 28, 2017, $32M — SB China Venture Capital, Youchoose Capital, Shenzhen Qianhai Kexin Capital Management
- Angel, Mar 21, 2015 — Sunland Capital

## Investors

- Sunland Capital — Angel
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A, Series D
- Youchoose Capital — Series A
- Shenzhen Qianhai Kexin Capital Management — Series A
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B
- Yuanzhi Venture Capital (https://capitalatlas.ai/funds/yuanzhi-venture-capital) — Series B
- CNCB (Hong Kong) Investment (https://capitalatlas.ai/funds/cncb-hong-kong-investment) — Series D
- Beijing Tongrentang Senior Care Investment Management (https://capitalatlas.ai/funds/beijing-tongrentang-senior-care-investment-management) — Series D